Purpose: F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Methods: Seventeen patients with proven cardiac amyloidosis underwent F-florbetapir PET/CT imaging, 15 with AL and 2 with transthyretin amyloidosis (ATTR). Three patients had repeat scans. All patients had protocolized assessment at the UK National Amyloidosis Centre including imaging with I-serum amyloid P component (SAP). F-Florbetapir images were assessed for areas of increased tracer accumulation and time-uptake curves in terms of standardized uptake values (SUV) were produced.
Results: All 17 patients showed F-florbetapir uptake at one or more extracardiac sites. Uptake was seen in the spleen in 6 patients (35%; 6 of 9, 67%, with splenic involvement on I-SAP scintigraphy), in the fat in 11 (65%), in the tongue in 8 (47%), in the parotids in 8 (47%), in the masticatory muscles in 7 (41%), in the lungs in 3 (18%), and in the kidney in 2 (12%) on the late half-body images. The F-florbetapir spleen retention index (SRI) was calculated. SRI >0.045 had 100% sensitivity/sensitivity (in relation to I-SAP splenic uptake, the current standard) in detecting splenic amyloid on dynamic imaging and a sensitivity of 66.7% and a specificity of 100% on the late half-body images. Intense lung uptake was seen in three patients, one of whom had lung interstitial infiltration suggestive of amyloid deposition on previous high-resolution CT. Repeat imaging showed a stable appearance in all three patients suggesting no early impact of treatment response.
Conclusion: F-Florbetapir PET/CT is a promising tool for the detection of extracardiac sites of amyloid deposition. The combination of uptake in the heart and uptake in the spleen on F-florbetapir PET/CT, a hallmark of AL, suggests that this tracer holds promise as a screening tool for AL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953997 | PMC |
| http://dx.doi.org/10.1007/s00259-018-3995-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Stratification of Light-Chain Cardiac Amyloidosis With F-Florbetapir and Ga-FAPI-04 for Enhanced Prognostic Precision.
JACC Cardiovasc Imaging
January 2025
Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Cardiac involvement in amyloid light chain (AL) amyloidosis significantly influences prognosis, necessitating timely diagnosis and meticulous risk stratification.
Objectives: This prospective study aimed to delineate the molecular phenotypes of AL cardiac amyloidosis (AL-CA) by characterizing fibro-amyloid deposition using F-florbetapir and gallium-68-labeled fibroblast activation protein inhibitor-04 (Ga-FAPI-04) positron emission tomography (PET)/computed tomography (CT) imaging. The authors also proposed a novel molecular stratification methodology for prognosis.
Ultra-fast [F]florbetapir PET imaging using the uMI Panorama PET/CT system.
EJNMMI Phys
December 2024
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Background: There is a need for faster amyloid PET scans to reduce patients' discomfort, minimize movement artifacts, and increase throughput. The recently introduced uMI Panorama PET/CT system featuring enhanced spatial resolution and sub-200ps TOF offers the potential for shorter scan duration without sacrificing image quality or efficacy to detect Aβ deposition. The study aims to establish a faster acquisition protocol for [F]florbetapir PET imaging using digital PET/CT scanner uMI Panorama, while ensuring adequate image quality and amyloid-β (Aβ) detectability comparable to the standard 10-minute scan.
View Article and Find Full Text PDFMultitracer PET/CT Findings in a Case of Behavioral Variant Frontotemporal Dementia With Parkinsonism.
Clin Nucl Med
February 2025
From the Departments of Neurology.
We report the clinical and multimodal PET/CT manifestations in a patient with behavioral variant frontotemporal dementia and parkinsonism. The 18 F-FDG PET scan revealed hypometabolism in the left supratentorial cortex. The 18 F-fluorodopa PET scan demonstrated decreased uptake in the bilateral striatum, most prominent in the head of caudate nucleus.
View Article and Find Full Text PDFPlasma Glial Fibrillary Acid Protein and Phosphorated Tau 181 Association with Presynaptic Density-Dependent Tau Pathology at F-SynVesT-1 Brain PET Imaging.
Radiology
November 2024
From the Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, China (J. Wu, J. Wang, Q.H., K.H., Y.G., F.X.); Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (B.L.); Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China (X.C., Z.Y., J.Z.); Department of Gerontology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, China (Q.G.); PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Conn (S.L., Y.H.H.); Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China (T.G.); Center for Applied Statistics, Institute of Statistics and Big Data, Renmin University of China, Beijing, China (W.D.); and Shanghai Conlight Medical Laboratory, Shanghai, China (W.X., W.C., D.Y.).
Background Synaptic loss is an important factor in Alzheimer disease (AD); however, blood assays that conveniently and rapidly reflect changes in synaptic density are lacking. Purpose To correlate multiple potential synaptic blood markers with synaptic density measured using F-SynVesT-1, a fluorine 18 (F)-labeled radiotracer, brain PET and to explore the independent associations between these markers and synaptic density. Materials and Methods This prospective study included 50 cognitively unimpaired (mean age, 65.
View Article and Find Full Text PDFEvaluation of ComBat Harmonization for Reducing Across-Tracer Differences in Regional Amyloid PET Analyses.
Hum Brain Mapp
November 2024
Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Differences in amyloid positron emission tomography (PET) radiotracer pharmacokinetics and binding properties lead to discrepancies in amyloid-β uptake estimates. Harmonization of tracer-specific biases is crucial for optimal performance of downstream tasks. Here, we investigated the efficacy of ComBat, a data-driven harmonization model, for reducing tracer-specific biases in regional amyloid PET measurements from [F]-florbetapir (FBP) and [C]-Pittsburgh compound-B (PiB).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!